Artificial Intelligence Needs Doctors As Much As They Need It

Artificial Intelligence Needs Doctors As Much As They Need It

In this futuristic medical concept, a doctor assesses a patient with robust machine assistance.

(© Elnur/Fotolia)


Keep Reading Keep Reading
Steven Haley
Steven Haley is a tech industry veteran and prolific angel investor. He is highly engaged at the leading edge of innovations through his company affiliations and in multiple capacities, which include advisor, operational roles, committee, and board member. He began his technology career working Numerically Controlled Systems (NC Machines), macro-assembler coding, applications hosted on mainframes and minicomputers, and broadband networking. Present-day initiatives relate to commercialization of software platforms. He has been involved in the healthcare sector for two decades serving on academic hospital boards, technology initiatives, and a medical investment advisory committee for a healthcare VC. He is also involved in numerous medical philanthropic activities, including establishing The BrainScience Foundation. His interest lie in adaptive learning software platforms, analytics, and the applications they support in healthcare, STEM education and enterprises.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.